Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics, Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation...
-
LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
-
FDA clearance enables initiation of Abpro’s first clinical-stage solid tumor program Clinical trial anticipated to commence in the first half of 2026 through Abpro’s global collaboration with...
-
IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents...
-
Jupiter, Florida, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic...
-
MicrobiotiX gains IND approval to initiate clinical trials for its pneumonia therapy designed to combat antibiotic-resistant superbugs.
-
Dewpoint Therapeutics today announced the opening of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for DPTX3186.
-
Lausanne, Switzerland — 1st October 2025 – HemostOD, a private Swiss company pioneering the ex vivo manufacturing of donor-free, off-the-shelf universal human blood platelets, today announced the...
-
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
-
FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.